Literature DB >> 15465628

Increased galanin receptor occupancy in Alzheimer's disease.

Pamela J McMillan1, Elaine Peskind, Murray A Raskind, James B Leverenz.   

Abstract

Increased galanin (GAL) may be associated with the cognitive deficits characteristic of Alzheimer's disease (AD). However, both increased and decreased GAL receptor density has been reported in AD brain. Previous studies indicate pre-treatment with guanine nucleotides displaces endogenous GAL from GAL receptors (GALR), providing an indirect measurement of GALR occupancy. In addition, pre-treatment with guanine nucleotides may provide a more accurate measurement of GALR density since it would avoid the masking of GALRs by residual binding of endogenous GAL. Thus, in the present study, we examined the influence of pre-treatment with guanine nucleotides on 125I-GAL binding in multiple regions of normal and AD brain. Our results indicate that GTP pre-treatment enhances GAL binding in specific regions in normal and AD brain. In addition, our results suggest an increase in the number of GALRs occupied by endogenous GAL in the deep layers of the frontal cortex and the lateral hypothalamus of AD subjects compared to normal subjects. The regional differences in GALR density and receptor occupancy between normal and AD subjects may play a role in the cognitive disturbances associated with the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465628     DOI: 10.1016/j.neurobiolaging.2004.01.004

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  5 in total

1.  Development of a high-throughput screening-compatible cell-based functional assay to identify small molecule probes of the galanin 3 receptor (GalR3).

Authors:  James Robinson; Anthony Smith; Emmanuel Sturchler; Sahba Tabrizifard; Theodore Kamenecka; Patricia McDonald
Journal:  Assay Drug Dev Technol       Date:  2013-10-12       Impact factor: 1.738

Review 2.  Neuroprotective role for galanin in Alzheimer's disease.

Authors:  Scott E Counts; Sylvia E Perez; Stephen D Ginsberg; Elliott J Mufson
Journal:  Exp Suppl       Date:  2010

Review 3.  Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease.

Authors:  J N Crawley
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

Review 4.  Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?

Authors:  S E Counts; S E Perez; E J Mufson
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

5.  Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2.

Authors:  Caroline R Elliott-Hunt; Fiona E Holmes; Dean M Hartley; Sylvia Perez; Elliott J Mufson; David Wynick
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.